SAFETY DATA SHEETS

This SDS packet was issued with item: 078934909

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078934908 078936616



	Section 1 - Identification			
(a)	Product Identifier:	Ampicillin and Sulbactam for Injection, USP		
(b)	NDC:	25021-142, 25021-143, 25021-144, 25021-186, 25021-187, 25021-188		
	Common/Trade Name:	Ampicillin Sodium / Sulbactam Sodium, Unasyn®		
	Chemical Name:	Ampicillin Sodium: monosodium – (2S, 5R, 6R)-6-[(R)-2- amino-2-phenylacetamido]-3, 3-dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylate		
		Sulbactam Sodium – sodium (2S, 5R)-3,3-dimethyl-7-oxo-4- thia- 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide		
	Chemical Family:	Antibiotics		
(c)	Product Use:	Treatment of infections due to susceptible strains of designated microorganisms in skin and skin structure infections, intra-abdominal infections, and gynecological infections.		
	Product Type:	Regulated Prescription Drug		
	Container Information:	Vials		
(d)	Distributor:	Sagent Pharmaceuticals, Inc., 1901 N. Roselle Rd, Suite 450, Schaumburg, IL 60195, 847-908-1600		
(e)	Emergency Telephone:	866-625-1618		

Section 2 - Hazards Identification

(a)	Classification:	HMIS Rating	
		Health Hazard	2
		Flammability	0
		Physical Hazard	0
		NFPA Rating	
		Health Hazard	2
		Fire Hazard	0

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 1 of 10



statement(s), Symbol(s), and/or Precautionary statement(s):	
Signal Word:	- WARNING
Hazard Statements: - - May cause allergic skin reaction - May cause allergic or asthmatic symptoms or breathing difficulties if inhaled - May cause damage to liver through prolonged or repeated exposure GHS Precautionary Statements: - - P260: Do not breathe dust/fume/gas/mist/vapors/spray - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. - If eye irritation persists, get medical attention. - Wash hands after handling.	

(d) Unknown Acute Toxicity: N/A

Section 3 –	Composition /	Information o	n Ingredients
	composition /	Intor mation 0	in ingi cuicitos

(a) Chemical Name	(b) Common Name / Synonym	% Composition or other measure	(c) CAS No.	(d) Impurities / Stabilizing Additives
monosodium – (2S, 5R, 6R)-6-[(R)-2-amino-2- phenylacetamido]-3, 3- dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane- 2-carboxylate	Ampicillin Sodium	66.66% (w/w)	69-52-3	N/A
sodium (2S, 5R)-3,3- dimethyl-7-oxo-4-thia- 1- azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide	Sulbactam Sodium	33.33% (w/w)	69388-84-7	N/A

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 2 of 10



	Section 4 - First Aid Measures
Eye Exposure:	Immediately flush eyes with water for at least 15 minutes. Seek medical attention.
Skin Exposure:	Remove contaminated clothing immediately. Flush area with water for at least 15 minutes. Wash exposed area with soap and water. Seek medical attention if pain, redness, or swelling persists.
Ingestion:	Flush mouth out with water immediately. Seek medical attention.
Injection:	See patient package insert in shipping carton for complete information.
Inhalation:	Move exposed subject to fresh air immediately. Give artificial respiration and cardiopulmonary resuscitation (CPR) if required. Seek medical attention.
Notes to Physician:	See patient package insert in shipping carton for complete information

	Section 5 – Fire-fighting Measures		
(a)	Extinguishing Media	Use extinguishing media appropriate for primary cause of fire (water, carbon dioxide or dry chemical). Use water spray to cool fire exposed containers. Wear self-containing breathing apparatus and protective clothing.	
(b)	Hazardous Combustion Products:	Emits toxic fumes of carbon monoxide, carbon dioxide, oxides of nitrogen, sulfur oxides, and other sulfur-containing compounds. Ash remaining after thermal decomposition may contain cyanide compounds and should not come in contact with acidic condition.	
(c)	Special Protective Equipment / Precautions:	Water spray, dry chemical, or carbon dioxide as appropriate to surroundings.	

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 3 of 10



	Section 6 - Accidental Release Measures
Spill:	Collect spilled powder using techniques that minimize powder migration. Clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.
Release to Air:	A system of local and/or general exhaust is recommended to keep employee exposure below the Airborne Exposure Limits. Local exhaust ventilation is generally preferred because it can control the emissions of the contaminant at its source, preventing dispersion of it into the general work area. Use explosion-proof equipment.
	This material must be handled in cool, well ventilated low humidity areas.
Release to Water:	Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

Section 7 - Handling and Storage		
General Handling:	When handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mist, and/or vapors associated with the product.	
Storage Conditions:	Store at 20°-25°C (68°-77°F), with excursions permitted between 15° and 30°C (59° and 86°F) prior to reconstitution. [See USP Controlled Room Temperature]. Follow instructions provided in packaging.	

Section 8 - Exposure Controls / Personal Protection

(a) Exposure Limits

Compound	Issuer	Туре	Exposure Limit
Ampicillin Sodium	OSHA	PEL	NE
-	ACGIH	TLV	NE
		STEL	NE
Sulbactam Sodium	OSHA	PEL	NE
	ACGIH	TLV	NE
		STEL	NE

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 4 of 10



TWA- 8 hours	3 mg/m^3 (as free
	acid)

(b) Engineering Controls

Ventilation: Local exhaust ventilation is required unless used in a closed system.

(c) Individual Protection Measures

Respiratory Protection:	With satisfactory ventilation, respiratory protection is usually not required.
Eye Protection:	Safety glasses or goggles recommended.
Skin Protection:	Disposable garments if direct skin contact is anticipated.
Other Protective Equipment:	Protective laboratory coat, apron, or disposable garment recommended.
Additional Exposure Precautions:	No eating, drinking or smoking while handling this product. Use good personal hygiene.

Section 9 - Physical and Chemical Properties

(a)	Appearance	White to off-white dry powder
(b)	Odor	No Odor
(c)	Odor Threshold	None
(d)	рН	8-10
(e)	Melting Point:	Not available
(f)	Initial Boiling Point:	Not available
(g)	Flash Point	Not available
(h)	Evaporation Rate:	Approx. to water
(i)	Flammability	Not flammable
(j)	Upper Lower Flammability or Explosion Limits	Not available
(k)	Vapor Pressure:	Not available
(l)	Vapor Density:	Not available
(m)	Relative Density	Approx. to water

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 5 of 10

Sagent Pharmaceuticals, Inc.				
Document Type	Document Title			
Safety Data Sheet (SDS) Ampicilln and Sulbactam for Injection, USP			JSP	
Document No).	Version	Effective Date	
MSDS-002	5	4.0	29 Apr 2020	

(n)	Solubility(ies)	Soluble in water
(0)	Partition Coefficient: n-octanol/water	Not available
(p)	Auto-ignition Temperature	Not available
(q)	Decomposition Temperature	Not available
(r)	Viscosity	Not available

Section 10 - Stability and Reactivity

(a)	Reactivity	Not available
(b)	Chemical Stability	Stable
(c)	Possibility of Hazardous Reactions	Hazardous polymerization does not occur
(d)	Conditions to Avoid	Avoid strong bases and strong acids.
(e)	Incompatible Materials	Strong oxidizing agents
(f)	Hazardous Decomposition Products	Carbon monoxide, carbon dioxide, oxides of nitrogen, sulfur oxides and other sulfur-containing compounds.

Section 11 - Toxicological Information

(a)	Likely Routes of Exposure	Inhalation, eye/skin contact, or ingestion.	
(b)	Symptoms related to the physical, chemical and toxicological characteristics	This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Possible adverse reactions include: diarrhea, rash, itching, nausea, vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension, glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat, substernal pain, epistaxis, and mucosal bleeding.	
(c)	Delayed and immediate effects and also chronic effects from short and long term exposure	Overdosage adverse reactions include neurological adverse reactions including convulsions. Ampicillin is reported to induce environmental or occupational asthma.	

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 6 of 10

	Docum Safety Data

Sagent Pharmaceuticals, Inc.			
Document Type	Document Title		
Safety Data Sheet (SDS)	heet (SDS) Ampicilln and Sulbactam for Injection, USP		
Document No.		Version	Effective Date
MSDS-0025		4.0	29 Apr 2020

(d) Acute Toxicity

Component	Туре	Route	Species	Dosage
Ampicillin	LD50	Oral	Rat	> 5314 mg/kg
Sodium				
Ampicillin	LD50	Subcutaneous	Rat	> 5314 mg/kg
Sodium				
Ampicillin	LD50	Intraperitoneal	Rat	7400 mg/kg
Sodium				
Ampicillin	LD50	Oral	Mouse	> 5314 mg/kg
Sodium				
Ampicillin	LD50	Subcutaneous	Mouse	> 5314 mg/kg
Sodium				
Ampicillin	LD50	Intraperitoneal	Mouse	5700 mg/kg
Sodium				
Sulbactam	LD50	Oral	Rat	> 4000 mg/kg
Sodium				
Sulbactam	LD50	Intravenous	Rat	4582 mg/kg
Sodium				
Sulbactam	LD50	Oral	Mouse	> 10,000 mg/kg
Sodium				
Sulbactam	LD50	Intravenous	Mouse	3604 mg/kg
Sodium				

Sulbactam Sodium was not teratogenic in studies in mice, rats, and rabbits. Two reports in which high oral doses of ampicillin did not produce teratogenic effects in rats. A third report identified high doses of ampicillin associated with limb defects.

(e) Hazardous Chemical Listings

NTP: Not Listed IARC: Not Listed

OSHA: Not Listed NI

NIOSH: Not listed

Section 12 - Ecological Information

(a)	Ecotoxicity	No applicable ecological information found.
(b)	Persistence and degradability	No applicable ecological information found.
(c)	Bioaccumulative potential	No applicable ecological information found.
(d)	Mobility in soil	No applicable ecological information found.
(e)	Other Adverse Effects	No applicable ecological information found.

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 7 of 10



Section 13 - Disposal Considerations

Follow federal, state and local regulations.

Section 14 - Transport Information

(a)	UN Number	Not available
(b)	UN Proper Shipping Name	Not available
(c)	Transport Hazard Class(es)	Not available
(d)	Packing Group	Not available
(e)	Environmental Hazards	Not available
(f)	Transport in bulk (according to Annex II of MARPOL 73/78 and the IBC Code)	Not available
(g)	Special Precautions	Not available

DOT: Not regulated **ICAO/IATA:** Not regulated **IMDG:** Not regulated

Section 15 - Regulatory Information

Below is selected regulatory information chosen primarily for possible Sagent usage. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your country/state.

U.S. Regulations:

TSCA - No CERCLA - Not on this list SARA 302 - Not on this list SARA 313 - Not on this list OSHA Substance Specific - No California Proposition 65 – Not Listed

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 8 of 10



Section 16 - Other Information

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact: Sagent Pharmaceuticals, Inc. 1901 N. Roselle Rd, Suite 450 Schaumburg, IL 60195 847-908-1600

Glossary: This glossary contains definitions of general terms used in SDSs. Not all of these				
Glossary Terms w	vill apply to this SDS.			
ACGIH	American Conference of Governmental Industrial Hygienists			

ACGIH	American Conference of Governmental Industrial Hygienists	
AIHA	American Industrial Hygiene Association	
CAS Number	Chemical Abstract Service Registry Number	
CERCLA	Comprehensive Environmental Response Compensation and Liability Act (of 1980)	
CHAN	Chemical Hazard Alert Notice	
CHEMTREC	Chemical Transportation Emergency Center	
DOT	Department of Transportation	
EPA	Environmental Protection Agency	
HEPA	High Efficiency Particulate Air (Filter)	
IARC	International Agency for Research on Cancer	
ICAO/IATA	International Civil Aviation Organization/International Air Transport	
	Association	
IMO	International Maritime Organization	
KOW	Octanol/Water Partition Coefficient	
LEL	Lower Explosive Limit	
MSDS	Material Safety Data Sheet	
MSHA	Mine Safety and Health Administration	
NA	Not Applicable, except in Section 14 where NA = North America	
NE	Not Established	
NADA	New Animal Drug Application	
NAIF	No Applicable Information Found	

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 9 of 10

Sagent Pharmaceuticals, Inc.			
Document Type Document Title			
Safety Data Sheet (SDS)	Ampicilln and Sulbactam for Injection, USP		
Document No).	Version	Effective Date
MSDS-002	5	4.0	29 Apr 2020

NCI	National Cancer Institute
NIOSH	National Institute for Occupational Safety and Health
NOS	Not Otherwise Specified
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
OEL	Occupational Exposure Limit
PEL	Permissible Exposure Limit (OSHA)
RCRA	Resource Conservation and Recovery Act
RQ	Reportable Quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SDS	Safety Data Sheet
STEL	Short Term Exposure Limit
TLV	Threshold Limit Value (ACGIH)
TPQ	Threshold Planning Quantity
TSCA	Toxic Substances Control Act
TWA	Time Weighted Average/8 Hours Unless Otherwise Noted
UEL	Upper Explosive Limit
UN	United Nations
USP	United States Pharmacopeia
WEEL	Workplace Environmental Exposure Level (AIHA)

Previous Document No	Confidential - For Use Only By Affiliates	Page
SDS027	of Sagent Pharmaceuticals, Inc.	Page 10 of 10